Literature DB >> 16237566

R561C missense mutation in the SMARCAL1 gene associated with mild Schimke immuno-osseous dysplasia.

Arend Bökenkamp1, Miranda deJong, Joanna A E van Wijk, Diana Block, Johanna M van Hagen, Michael Ludwig.   

Abstract

Autosomal-recessive Schimke immuno-osseous dysplasia (SIOD) characterized by spondyloepiphyseal dysplasia, focal-segmental glomerulosclerosis (FSGS), T-cell immunodeficiency and facial dysmorphism is caused by defects in the SMARCAL1 gene. The gene product is involved in the transcriptional regulation of other genes. A 12-year-old boy of consanginous Turkish descent developed disproportionate short stature from spondyloepiphyseal dysplasia at the age of 6 and nephrotic syndrome at the age of 10 years. Renal biopsy revealed FSGS, the kidney function was normal, T-lymphocytes were diminished without infectious complications, and he has had no cerebral ischemia. Analysis of the patient's SMARCAL1 gene revealed a novel homozygous C1798T transition leading to a R561C substitution. The parents and two healthy sisters were found to be heterozygous. A younger brother, who is also homozygous for the mutation, is clinically asymptomatic and has no proteinuria at the age of 18 months. Still, his CD4 cells are diminished. For SMARCAL1 mutations a clear genotype-phenotype correlation has been reported: severe SIOD with in utero or early-childhood onset leading to end-stage renal disease within a few years is caused by nonsense, frame shift or splice mutations. Many patients die from infections and cerebrovascular insults during childhood. Mild SIOD manifests later and progresses more slowly without infectious or cerebral vascular complications--the underlying defect being missense mutations in all three patients reported so far. The novel R561C missense mutation in our patient with mild SIOD is additional evidence for the genotype-phenotype correlation reported for SMARCAL1 mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237566     DOI: 10.1007/s00467-005-2047-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

1.  Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literature.

Authors:  C F Boerkoel; S O'Neill; J L André; P J Benke; R Bogdanovíć; M Bulla; A Burguet; S Cockfield; I Cordeiro; J H Ehrich; S Fründ; D F Geary; A Ieshima; F Illies; M W Joseph; I Kaitila; G Lama; B Leheup; M D Ludman; D R McLeod; A Medeira; D V Milford; T Ormälä; Z Rener-Primec; A Santava; H G Santos; B Schmidt; G C Smith; J Spranger; N Zupancic; R Weksberg
Journal:  Eur J Pediatr       Date:  2000 Jan-Feb       Impact factor: 3.183

Review 2.  Chromatin remodeling and human disease.

Authors:  Cheng Huang; Emily A Sloan; Cornelius F Boerkoel
Journal:  Curr Opin Genet Dev       Date:  2003-06       Impact factor: 5.578

3.  Schimke immuno-osseous dysplasia: a newly recognized multisystem disease.

Authors:  J Spranger; G K Hinkel; H Stöss; W Thoenes; D Wargowski; F Zepp
Journal:  J Pediatr       Date:  1991-07       Impact factor: 4.406

4.  Cloning and characterization of HARP/SMARCAL1: a prokaryotic HepA-related SNF2 helicase protein from human and mouse.

Authors:  M A Coleman; J A Eisen; H W Mohrenweiser
Journal:  Genomics       Date:  2000-05-01       Impact factor: 5.736

5.  Chondroitin-6-sulphaturia, defective cellular immunity, and nephrotic syndrome.

Authors:  R N Schimke; W A Horton; C R King
Journal:  Lancet       Date:  1971-11-13       Impact factor: 79.321

Review 6.  SWI2/SNF2 and related proteins: ATP-driven motors that disrupt protein-DNA interactions?

Authors:  M J Pazin; J T Kadonaga
Journal:  Cell       Date:  1997-03-21       Impact factor: 41.582

Review 7.  Juvenile variant of Schimke immunoosseous dysplasia.

Authors:  K Hashimoto; A Takeuchi; A Ieshima; M Takada; M Kasagi
Journal:  Am J Med Genet       Date:  1994-02-01

8.  Generalized atherosclerosis sparing the transplanted kidney in Schimke disease.

Authors:  Thomas Lücke; Katja M Marwedel; Nele K Kanzelmeyer; Akira Hori; Gisela Offner; Hans-Heinrich Kreipe; Jochen H H Ehrich; Anibh M Das
Journal:  Pediatr Nephrol       Date:  2004-03-31       Impact factor: 3.714

9.  Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold.

Authors:  J E Walker; M Saraste; M J Runswick; N J Gay
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

10.  Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes.

Authors:  A E Gorbalenya; E V Koonin; A P Donchenko; V M Blinov
Journal:  Nucleic Acids Res       Date:  1989-06-26       Impact factor: 16.971

View more
  10 in total

1.  Penetrance of biallelic SMARCAL1 mutations is associated with environmental and genetic disturbances of gene expression.

Authors:  Alireza Baradaran-Heravi; Kyoung Sang Cho; Bas Tolhuis; Mrinmoy Sanyal; Olena Morozova; Marie Morimoto; Leah I Elizondo; Darren Bridgewater; Joanna Lubieniecka; Kimberly Beirnes; Clara Myung; Danny Leung; Hok Khim Fam; Kunho Choi; Yan Huang; Kira Y Dionis; Jonathan Zonana; Kory Keller; Peter Stenzel; Christy Mayfield; Thomas Lücke; Arend Bokenkamp; Marco A Marra; Maarten van Lohuizen; David B Lewis; Chad Shaw; Cornelius F Boerkoel
Journal:  Hum Mol Genet       Date:  2012-02-28       Impact factor: 6.150

2.  Steroid-resistant nephrotic syndrome in a child with dysmorphic features: answers.

Authors:  Osama Safdar; Sherif M El-Desoky; Detlef Bockenhauer; Neil Sebire; Neil Sabire; Jameela A Kari
Journal:  Pediatr Nephrol       Date:  2014-01-29       Impact factor: 3.714

Review 3.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 4.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

5.  Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child.

Authors:  Clinton Carroll; Akosua Badu-Nkansah; Tracy Hunley; Alireza Baradaran-Heravi; David Cortez; Haydar Frangoul
Journal:  Pediatr Blood Cancer       Date:  2013-04-29       Impact factor: 3.167

6.  Progress in pathogenesis of proteinuria.

Authors:  Aihua Zhang; Songming Huang
Journal:  Int J Nephrol       Date:  2012-05-24

7.  A novel compound heterozygous mutation of the SMARCAL1 gene leading to mild Schimke immune-osseous dysplasia: a case report.

Authors:  Shuaimei Liu; Mingchao Zhang; Mengxia Ni; Peiran Zhu; Xinyi Xia
Journal:  BMC Pediatr       Date:  2017-12-28       Impact factor: 2.125

8.  A novel SMARCAL1 mutation associated with a mild phenotype of Schimke immuno-osseous dysplasia (SIOD).

Authors:  Luisa Santangelo; Maddalena Gigante; Giuseppe Stefano Netti; Sterpeta Diella; Flora Puteo; Vincenza Carbone; Giuseppe Grandaliano; Mario Giordano; Loreto Gesualdo
Journal:  BMC Nephrol       Date:  2014-03-03       Impact factor: 2.388

9.  Expanding Phenotype of Schimke Immuno-Osseous Dysplasia: Congenital Anomalies of the Kidneys and of the Urinary Tract and Alteration of NK Cells.

Authors:  Cristina Bertulli; Antonio Marzollo; Margherita Doria; Silvia Di Cesare; Claudio La Scola; Francesca Mencarelli; Andrea Pasini; Maria Carmen Affinita; Enrico Vidal; Pamela Magini; Paola Dimartino; Riccardo Masetti; Laura Greco; Patrizia Palomba; Francesca Conti; Andra Pession
Journal:  Int J Mol Sci       Date:  2020-11-15       Impact factor: 5.923

10.  A novel compound heterozygous variant in SMARCAL1 leading to mild Schimke immune-osseous dysplasia identified using whole-exome sequencing.

Authors:  Li Wang; Jingjing Li; Ge Wu; Xiangdong Kong
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.